Stockreport

Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour Coughs Per Hour Compared to Placebo at Week 12 and 24 in Phase 3 Trials KENI [Read more]